User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

POR∗28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia

Primary tabs

Ragia, Georgia Mollaki, Vasiliki Elens, Laure Van Schaik, Ron HN Manolopoulos, Vangelis G.

Background: In children and adolescents with familial hypercholesterolemia (FH) pharmacotherapy with statins is the cornerstone in the current regimen to reduce low-density lipoprotein cholesterol (LDLc) and premature coronary heart disease risk. There is, however, a great interindividual variation in response to therapy, partially attributed to genetic factors. The polymorphic enzyme POR transfers electrons from NADPH to CYP450 enzymes including CYP3A, which metabolize atorvastatin. POR∗28 polymorphism is associated with increased CYP3A enzyme activity. We analyzed the association of POR∗28 allele with response to atorvastatin. Materials & methods: One hundred and five FH children and adolescents treated with atorvastatin at doses 10-40 mg were included in the study. Total cholesterol (TChol) and LDLc were measured at baseline and after 6 months of treatment. POR∗28 allele was analyzed with TaqMan assay. CYP3A4∗22, CYP3A5∗3 and SLCO1B1 521T>C and 388A>G genotypes were also determined with TaqMan or PCR-RFLP methods. Results: POR∗28 carriers had significantly lower percent mean reduction of TChol (33.1% in ∗1/∗1, 29.8% in ∗1/∗28 and 25.9% in ∗28/∗28 individuals, p = 0.045) and of LDLc (43.9% in ∗1/∗1, 40.9% in ∗1/∗28 and 30.8% in ∗28/∗28 individuals, p = 0.013). In multivariable linear regression adjusted for confounding factors, POR∗28 genotypes, additionally to baseline cholesterol level, accounted for an estimated 8.3% and 7.3% of overall variability in % TChol and LDLc reduction (β: 4.05; 95% CI: 1.73-6.37; p = 0.001 and β: 5.08; 95% CI: 1.62-8.54; p = 0.004, respectively). CYP3A4∗22, CYP3A5∗3 and SLCO1B1 521T>C and 388A>G polymorphisms were not associated with lipid reductions and did not modify the effect of POR∗28 on atorvastatin response. Conclusion: In children with FH, carriage of POR∗28 allele is associated with reduced effect of atorvastatin on TChol and LDLc and therefore identifies FH children that may require higher atorvastatin doses to achieve full therapeutic benefits. Additional studies in different populations are needed to replicate this association.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2014
Language Anglais
Journal information "Pharmacogenomics" - Vol. 15, no. 16, p. 1963-1972 (2014)
Peer reviewed yes
Publisher Future Medicine Ltd.
e-issn 1744-8042
issn 1462-2416
Publication status Publié
Links
  1. van Aalst-Cohen Emily, Jansen Angelique, de Jongh Saskia, de Sauvage Nolting Pernette, Kastelein John, Clinical, Diagnostic, and Therapeutic Aspects of Familial Hypercholesterolemia, 10.1055/s-2004-822984
  2. Ito Matthew K., McGowan Mary P., Moriarty Patrick M., Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, 10.1016/j.jacl.2011.04.001
  3. Justo Robert N, Management of familial hypercholesterolaemia in children and adolescents : Familial hypercholesterolaemia, 10.1111/j.1440-1754.2011.02206.x
  4. Descamps O.S., Tenoutasse S., Stephenne X., Gies I., Beauloye V., Lebrethon M.-C., De Beaufort C., De Waele K., Scheen A., Rietzschel E., Mangano A., Panier J.P., Ducobu J., Langlois M., Balligand J.-L., Legat P., Blaton V., Muls E., Van Gaal L., Sokal E., Rooman R., Carpentier Y., De Backer G., Heller F.R., Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization, 10.1016/j.atherosclerosis.2011.06.016
  5. Daniels Stephen R., Gidding Samuel S., de Ferranti Sarah D., Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, 10.1016/j.jacl.2011.03.453
  6. Braamskamp Marjet J.A.M., Wijburg Frits A., Wiegman Albert, Drug Therapy of Hypercholesterolaemia in Children and Adolescents : , 10.2165/11632810-000000000-00000
  7. Stein EA, Nutr. Metab. Cardiovasc. Dis., 11, 24 (2001)
  8. Superko H. Robert, Momary Kathryn M., Li Yonghong, Statins Personalized, 10.1016/j.mcna.2011.11.004
  9. Puccetti Luca, Acampa Maurizio, Auteri Alberto, Pharmacogenetics of Statins Therapy, 10.2174/157489007782418982
  10. Park J.-E., Kim K.-B., Bae S. K., Moon B.-S., Liu K.-H., Shin J.-G., Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin, 10.1080/00498250802334391
  11. Flück Christa E., Nicolo Catherine, Pandey Amit V., Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase, 10.1111/j.1472-8206.2007.00520.x
  12. Riddick D. S., Ding X., Wolf C. R., Porter T. D., Pandey A. V., Zhang Q.-Y., Gu J., Finn R. D., Ronseaux S., McLaughlin L. A., Henderson C. J., Zou L., Fluck C. E., NADPH-Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology, 10.1124/dmd.112.048991
  13. Agrawal Vishal, Huang Ningwu, Miller Walter L., Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19 : , 10.1097/fpc.0b013e32830054ac
  14. Gomes Ana M, Winter Stefan, Klein Kathrin, Turpeinen Miia, Schaeffeler Elke, Schwab Matthias, Zanger Ulrich M, Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation, 10.2217/pgs.09.7
  15. Oneda Beatrice, Crettol Severine, Sirot Evelyne Jaquenoud, Bochud Murielle, Ansermot Nicolas, Eap Chin B., The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test : , 10.1097/fpc.0b013e32833225e7
  16. Zhang Jing-Jing, Zhang Hua, Ding Xiao-Liang, Ma Sheng, Miao Li-Yan, Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers, 10.1007/s00228-012-1432-1
  17. de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk RJ, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients, 10.2217/pgs.11.77
  18. Pediatrics, 128, S213 (2011)
  19. Mollaki Vasiliki, Progias Pavlos, Drogari Euridiki, NovelLDLRVariants in Patients with Familial Hypercholesterolemia:In SilicoAnalysis as a Tool to Predict Pathogenic Variants in Children and Their Families : In SilicoAnalysis of NovelLDLRVariants, 10.1111/ahg.12032
  20. Ragia G, Drug Metabol. Drug Interact. (2014)
  21. Arvanitidis Kostas, Ragia Georgia, Iordanidou Maria, Kyriaki Sofia, Xanthi Athanasia, Tavridou Anna, Manolopoulos Vangelis G., Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population, 10.1111/j.1472-8206.2007.00510.x
  22. Giannakopoulou E., Ragia G., Kolovou V., Tavridou A., Tselepis A. D., Elisaf M., Kolovou G., Manolopoulos V. G., No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population, 10.1007/s11033-014-3334-z
  23. Weir B, Genetic Data Analysis II. (1996)
  24. Ragia G., Tavridou A., Elens L., Van Schaik R., Manolopoulos V., CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas, 10.1055/s-0033-1361097
  25. Ragia Georgia, Kolovou Vana, Tavridou Anna, Elens Laure, Tselepis Alexandros D., Elisaf Moses, Van Schaik Ron H. N., Kolovou Genovefa, Manolopoulos Vangelis G., Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients, 10.1007/s40291-013-0082-z
  26. Sandee Duanpen, Morrissey Kari, Agrawal Vishal, Tam Harrison K., Kramer Melissa A., Tracy Timothy S., Giacomini Kathleen M., Miller Walter L., Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro : , 10.1097/fpc.0b013e32833f4f9b
  27. Subramanian Murali, Agrawal Vishal, Sandee Duanpen, Tam Harrison K., Miller Walter L., Tracy Timothy S., Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3 : , 10.1097/fpc.0b013e3283544062
  28. Yang Guoping, Fu Zhimin, Chen Xiaoping, Yuan Hong, Yang Heng, Huang Yuanyuan, Ouyang Dongsheng, Tan Zhirong, Tan Hongyi, Huang Zhijun, Zhou Honghao, Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men, 10.1016/j.clinthera.2011.11.004
  29. Agrawal Vishal, Choi Ji Ha, Giacomini Kathleen M., Miller Walter L., Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase : , 10.1097/fpc.0b013e32833e0cb5
  30. Miltiadous George, Xenophontos Stavroulla, Bairaktari Eleni, Ganotakis Manolis, Cariolou Marios, Elisaf Moses, Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia : , 10.1097/01213011-200504000-00005
  31. Mohrschladt Martina F, van der Sman-de Beer Femke, Hofman Maaike K, van der Krabben Marieke, Westendorp Rudi GJ, Smelt August HM, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia, 10.1038/sj.ejhg.5201426
  32. García-García Ana B., González Cintia, Real José T., Martín de Llano José J., González-Albert Verónica, Civera Miguel, Chaves Felipe J., Ascaso Juan F., Carmena Rafael, Influence of microsomal triglyceride transfer protein promoter polymorphism −493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia : , 10.1097/01213011-200504000-00004
  33. Christidis Dimitrios S., Liberopoulos Evangelos N., Kakafika Anna I., Miltiadous George A., Cariolou Marios, Ganotakis Emmanuel S., Mikhailidis Dimitri P., Elisaf Moses S., The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or Fenofibrate, 10.1177/1074248406293732
Bibliographic reference Ragia, Georgia ; Mollaki, Vasiliki ; Elens, Laure ; Van Schaik, Ron HN ; Manolopoulos, Vangelis G.. POR∗28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. In: Pharmacogenomics, Vol. 15, no. 16, p. 1963-1972 (2014)
Permanent URL http://hdl.handle.net/2078.1/160236